Pangea Biomed, a Tel Aviv, Israel-based biotech company, raised additional $5M in funding.
The round was led by Danny Tocatly and NFX.
The company intends to use the funds to expand US operations, drive commercial partnerships, and scale product offerings.
Led by Tuvik Beker, Emmanuel Elalouf, and Ranit Aharonov, Pangea Biomed developed ENLIGHT – an advanced multi-cancer, multi-therapy response predictor. By combining machine learning and deep RNA analysis, the company is mapping tumor molecular signatures to dynamically and adaptively personalize cancer care for a healthier world. Pangea aims to bring effective precision oncology to cancer patients, improve oncology drug development and empower oncologists to treat patients with success.
Over the last year, the company began two clinical trials, published three papers on their newest findings and established partnerships with several pharmaceutical companies. Pangea is also actively collaborating with clinicians and researchers from some of the world’s best institutes, including Massachusetts General Hospital and Sheba Hospital, the largest hospital in Israel and one of the top ten hospitals in the world.
FinSMEs
16/12/2022